###begin article-title 0
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
Copy-number variation in BMPR2 is not associated with the pathogenesis of pulmonary arterial hypertension
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 146 152 146 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 101 104 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 174 177 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Copy-number variations (CNVs) are structural variations in the genome involving 1 kb to 3 mb of DNA. CNV has been reported within intron 1 of the BMPR2 gene. We propose that CNV could affect phenotype in familial and/or sporadic pulmonary arterial hypertension (PAH) by altering gene expression.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 217 220 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 280 283 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 346 349 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
97 human DNA samples were obtained which included 24 patients with familial PAH, 18 obligate carriers (BMPR2 mutation positive), 20 sporadic PAH patients, and 35 controls. Two sets of primers were designed within the CNV, and two sets of control primers were designed outside the CNV. Quantitative PCR was performed to quantify genomic copies of CNV and control sequences.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 2 5 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
A CNV in BMPR2 was present in one African American negative control subject.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 21 24 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
We conclude that the CNV in intron 1 in BMPR2 is unlikely to play a role in the pathogenesis of either familial or sporadic PAH.
###end p 9
###begin title 10
Trial Registration
###end title 10
###begin p 11
NIH NCT00091546.
###end p 11
###begin title 12
Background
###end title 12
###begin p 13
###xml 301 307 301 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 415 421 415 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 580 586 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 744 750 744 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 941 947 941 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 1062 1068 1062 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 1093 1094 1093 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1147 1152 1147 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2</italic>
###xml 1191 1197 1191 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 1259 1265 1259 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 1302 1308 1302 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 1326 1327 1326 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
###xml 1041 1049 <span type="species:ncbi:9606">patients</span>
###xml 1175 1183 <span type="species:ncbi:9606">patients</span>
###xml 1288 1296 <span type="species:ncbi:9606">patients</span>
Pulmonary arterial hypertension is a progressive disease characterized by obstruction of pre-capillary pulmonary arteries. Symptoms of PAH include fatigue and shortness of breath. Sustained pulmonary arterial hypertension eventually leads to right-sided heart failure and death. In 2000, mutations in BMPR2 (bone morphogenic protein receptor type 2) located on chromosome 2 were shown to cause familial PAH[1]. The BMPR2 gene spans 190 kb but encodes only a 4 kb transcript. It contains 13 exons and a large first intron composed of over 90 kb with frequent repetitive sequences. BMPR2 mutations are present in over 80% of patients diagnosed with familial PAH and are responsible for some cases of idiopathic PAH. Although the discovery of the BMPR2 mutation has enhanced our understanding of PAH, there are several important characteristics of the disease which remain unexplained. For example, the lifetime risk of developing PAH with the BMPR2 mutation is less than 20%, anticipation is observed, and there are both familial and sporadic patients without the BMPR2 mutation who develop PAH[2]. Recently, penetrance has been linked to levels of BMPR2; unaffected carriers (patients with a BMPR2 mutation who do not have PAH) have higher levels of wild-type BMPR2 allele transcript than patients with BMPR2 mutations and PAH[3]. This finding suggests that alterations of gene expression may be relevant to PAH phenotype.
###end p 13
###begin p 14
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 711 712 711 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 117 120 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 298 301 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 332 347 <span type="species:ncbi:10090">transgenic mice</span>
###xml 577 580 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
CNVs contribute to genetic variation through insertion, deletion, or inversion of DNA. Examples of diseases in which CNV participates mechanistically include DiGeorge syndrome, Angelman syndrome, Alzheimer's, autism, and schizophrenia[4]. Cystic fibrosis is an example of a pulmonary disease where CNV modulates gene expression. In transgenic mice, deletion of DNase I hypersensitive site in intron 1 did not change CFTR (cystic fibrosis transmembrane conductance regulator) expression in the lung, but it decreased expression of CFTR in the intestine by about 60%. Therefore, CNV in intron 1 in the CFTR gene acts as a regulatory element and is required for normal CFTR expression in the intestinal epithelium[5].
###end p 14
###begin p 15
###xml 309 315 309 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 385 386 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 492 498 492 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 473 476 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 551 554 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Recent advancements in array technology have allowed investigators to perform genome-wide assessments of genetic variation. To date, there are well over twenty thousand CNVs listed in the Database of Genomic Variants. The Database of Genomic Variants lists seven partially overlapping CNVs within intron 1 of BMPR2 on chromosome 2 consisting of a deletion of a several kilobase region[6]. Since intron 1 can contain regulatory elements, as demonstrated in cystic fibrosis, CNV in intron 1 of BMPR2 may be an important modifier in PAH. We propose that CNV in intron 1 of BMPR2 could affect penetrance, anticipation, or disease phenotype in familial and/or sporadic PAH.
###end p 15
###begin title 16
Methods
###end title 16
###begin p 17
###xml 64 70 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 49 52 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 316 319 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
The Database of Genomic Variants was queried for CNV within the BMPR2 gene. The database identified seven CNVs in intron 1 at locus 2q33.1: 202,992,448 - 203,030,002. The CNVs were partially overlapping, but had different endpoints (Figure 1). They were discovered using a variety of methodologies [6-12]. All seven CNV studies used samples from the International HapMap Project which includes individuals of European, Yoruba, Chinese, and Japanese ancestry.
###end p 17
###begin p 18
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CNV and primer set location in the <italic>BMPR2 </italic>genome</bold>
###xml 0 3 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
CNV and primer set location in the BMPR2 genome.
###end p 18
###begin p 19
###xml 297 303 297 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 364 370 364 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR1a</italic>
###xml 495 496 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 55 58 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 67 70 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 133 136 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 241 244 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 373 376 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 432 435 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
We designed two sets of primers within the overlapping CNV region: CNV set 1 (GCATTGAAAGTGGGATAATGG, TGAAATTTGAGGATAACAATTTTAAG) and CNV set 2 (TAATTGCCTTCAGAGCAGGG, CCAACATTTGTCAAGGATGC). We designed two sets of control primers outside the CNV (one control primer set was placed within exon 1 of BMPR2 and the other control primer set was placed within exon 1 of BMPR1a): CNV set 1 (TTGTGATTCGCTCACAGGAG, AGAGGCTGCCCCTTCTAGTC) and CNV set 2 (TGGTAAAGGCCGATATGGAG, ATGTTTTCATGGCGCATTAG) (Figure 1).
###end p 19
###begin p 20
###xml 375 381 375 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 516 522 516 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 621 627 621 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 760 766 760 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
###xml 852 857 <span type="species:ncbi:9606">child</span>
###xml 868 876 <span type="species:ncbi:9606">patients</span>
###xml 898 906 <span type="species:ncbi:9606">patients</span>
Human genomic DNA was obtained with informed consent from 97 patients with approval from the Institutional Review Board at Vanderbilt University. Genomic DNA was isolated from whole blood using the Roche MagNA Pure LC DNA purification system (Roche Molecular Biochemicals, Indianapolis, IN). Of the 97 samples, there were 24 patients with familial PAH, 18 obligate carriers (BMPR2 mutation positive), 20 sporadic PAH patients, and 35 controls. Obligate carriers are patients without pulmonary hypertension, but with BMPR2 mutations. Controls were either married-in spouses (7), unaffected family members negative for the BMPR2 mutation (13), or unrelated healthy individuals (14). There were 21 families with familial PAH included, representing on average 113 BMPR2 alleles. In efforts to evaluate penetrance and anticipation, we included seven parent-child dyads. 93 patients were Caucasian and 4 patients were African American.
###end p 20
###begin p 21
###xml 114 117 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
DNA samples were diluted to 2 ng/ml. Quantitative PCR with SYBR Green was performed to quantify genomic copies of CNV and controls. Samples were run in triplicates on an Applied Biosystems StepOnePlus machine. A dilution series was performed to quantify primer efficiency.
###end p 21
###begin title 22
Results and Disscusion
###end title 22
###begin p 23
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 508 514 508 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 0 3 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 55 58 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 137 140 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 182 185 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 376 379 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 501 504 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 521 528 <span type="species:ncbi:9606">patient</span>
CNV in BMPR2 was present in one out of 97 samples. The CNV was in an African American control and consisted of a loss of one copy of the CNV region. Figure 2 represents the ratio of CNV to genomic DNA in the control, obligate, familial, and sporadic patients. Small variation from a ratio of 1.0 is caused by noise inherent to the quantitative PCR process. Since the reported CNV from the HapMap Project contained individuals of European, Yoruba, Chinese, and Japanese ancestry, it is likely that the CNV in BMPR2 in our patient is attributable to an ethnic basis.
###end p 23
###begin p 24
###xml 0 89 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ratio of CNV to genomic DNA in the control, obligate, affected, and sporadic PAH patients</bold>
###xml 9 12 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Ratio of CNV to genomic DNA in the control, obligate, affected, and sporadic PAH patients.
###end p 24
###begin title 25
Conclusion
###end title 25
###begin p 26
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 243 249 243 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 352 358 352 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 146 149 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 236 239 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 268 275 <span type="species:ncbi:9606">patient</span>
###xml 290 297 <span type="species:ncbi:9606">patient</span>
###xml 341 344 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
The recent discovery of differences in levels of BMPR2 allele transcript among affected PAH patients and unaffected carriers led us to look for a CNV within the BMPR2 gene which could affect gene expression. We succeeded in identifying CNV in BMPR2 in intron 1 in one patient; however, the patient was a control subject. It is unlikely that CNV within BMPR2 intron 1 plays a role in the pathogenesis of either familial or sporadic PAH.
###end p 26
###begin title 27
List of Abbreviations
###end title 27
###begin p 28
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2</italic>
###xml 0 3 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
CNV: copy-number variation; BMPR2: bone morphogenic protein receptor type 2; PAH: pulmonary arterial hypertension; CFTR: cystic fibrosis transmembrane conductance regulator
###end p 28
###begin title 29
Competing interests
###end title 29
###begin p 30
The authors declare that they have no competing interests.
###end p 30
###begin title 31
Authors' contributions
###end title 31
###begin p 32
JJ drafted the manuscript and performed quantitative PCR, CV participated in the design of the study, JC participated in the design of the study, JL participated in the design of the study, JW participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript.
###end p 32
###begin title 33
Pre-publication history
###end title 33
###begin p 34
The pre-publication history for this paper can be accessed here:
###end p 34
###begin p 35

###end p 35
###begin article-title 36
Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium
###end article-title 36
###begin article-title 37
Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies
###end article-title 37
###begin article-title 38
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMPR2 </italic>
Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele
###end article-title 38
###begin article-title 39
Copy-number variations associated with neuropsychiatric conditions
###end article-title 39
###begin article-title 40
An element in intron 1 of the CFTR gene augments intestinal expression in vivo
###end article-title 40
###begin article-title 41
###xml 42 47 <span type="species:ncbi:9606">human</span>
Detection of large-scale variation in the human genome
###end article-title 41
###begin article-title 42
###xml 58 63 <span type="species:ncbi:9606">human</span>
Mapping and sequencing of structural variation from eight human genomes
###end article-title 42
###begin article-title 43
###xml 57 62 <span type="species:ncbi:9606">human</span>
A high-resolution survey of deletion polymorphism in the human genome
###end article-title 43
###begin article-title 44
Systematic assessment of copy number variant detection via genome-wide SNP genotyping
###end article-title 44
###begin article-title 45
###xml 37 42 <span type="species:ncbi:9606">human</span>
Common deletion polymorphisms in the human genome
###end article-title 45
###begin article-title 46
Integrated detection and population-genetic analysis of SNPs and copy number variation
###end article-title 46
###begin article-title 47
###xml 43 48 <span type="species:ncbi:9606">human</span>
The fine-scale and complex architecture of human copy-number variation
###end article-title 47

